DrugPatentWatch Database Preview
Valbenazine tosylate - Generic Drug Details
What are the generic sources for valbenazine tosylate and what is the scope of patent protection?
Valbenazine tosylate
is the generic ingredient in one branded drug marketed by Neurocrine and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Valbenazine tosylate has thirty-four patent family members in twenty countries.
One supplier is listed for this compound.
Summary for valbenazine tosylate
| International Patents: | 34 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 4 |
| Patent Applications: | 3 |
| DailyMed Link: | valbenazine tosylate at DailyMed |
Pharmacology for valbenazine tosylate
| Drug Class | Vesicular Monoamine Transporter 2 Inhibitor |
| Mechanism of Action | Vesicular Monoamine Transporter 2 Inhibitors |
Synonyms for valbenazine tosylate
| (2R,3R,11bR)-9,10-Dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-benzo(a)quinolizin-2-yl L-valinate bis(4-methylbenzenesulfonate) |
| 1639208-54-0 |
| 5SML1T733B |
| CHEMBL3707248 |
| D10999 |
| Ingrezza (TN) |
| L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester, 4-methylbenzenesulfonate (1:2) |
| NBI-98854 ditosylate |
| Q27262815 |
| s9500 |
| SCHEMBL18863051 |
| UNII-5SML1T733B |
| Valbenazine ditosylate |
| Valbenazine tosylate (USAN) |
| Valbenazine tosylate [USAN] |
US Patents and Regulatory Information for valbenazine tosylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-002 | Oct 4, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-002 | Oct 4, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-002 | Oct 4, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for valbenazine tosylate
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20090079257 | Start Trial |
| Japan | 2010509366 | Start Trial |
| Brazil | PI0718247 | Start Trial |
| Eurasian Patent Organization | 201890852 | Start Trial |
| Spain | 2402220 | Start Trial |
| European Patent Office | 2081929 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2017075340 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
NCE-1 Patent Challenge Dates 2020 - 2021
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2020, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
